. 2010 May 18;3(5):1576–1593. doi: 10.3390/ph3051576

Table 3.

Kinase inhibitors that directly and indirectly target Mdm2, Mdmx and p53.

Kinase	Inhibitor
c-Abl	imatinib^a [66], dasatinib^a,b [67,68], nilotinib^a,b [69], ON012380^c [70]
ATM	KU-55933^a [71], KU-60019^a [72], CP466722 [73]
CDK	SNS-032 [74], AT7519^a [75]
Chk1/Chk2	AZD7762^a [76]
CSN	curcumin
DNA-PK	morphlins [77], NU-7441^a [78], NU-7422^a [79], LY294002^a [80].
ERK	lapatinib^a [81]
JNK	SP600125^a [82]
MAPKAP2	pyrazinoindolone [83], subersic acid [84], makassaric acid [84]
PKC	ingenol 3-angelate^c [85,86], midostaurin^a [87], safingol [88]
TAF1	apigenin^a [89]

^a Type I inhibitors; ^b Type II inhibitors; ^c allosteric inhibitors; ^d irreversible covalent inhibitors.